Sanofi displeased with NICE decision on rare disease drug

14 March 2017

French drug major Sanofi (Euronext: SAN) and its specialty care global business unit, Sanofi Genzyme, say they are disappointed about the provisional recommendation by the England and Wales medicines cost-effectiveness regulator for one of their drugs.

The UK’s National Institute of Health and Care Excellence (NICE) has issued a provisional recommendation to not recommend Cerdelga (eliglustat) as a first-line oral treatment for adults with type 1 Gaucher disease in England.

THE NICE published its draft guidance today in an Evaluation Consultation Document (ECDV) , though this is not yet final guidance and may be subject to change.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK